The third round of testing and data logging for the enhanced AsepticSure™ technology is finally complete, as announced per Medizone International, Inc. The results from this program show greater than 6 logs of bacterial "kill" across the full spectrum of hospital contaminants including MRSA, C difficile, E coli, Pseudomonas aeruginosa and VRE in addition to the internationally accepted surrogate for Anthrax, Bacillus subtilis. Significantly, these results have been replicated on more than a single surface material.
"This latest round of laboratory testing has confirmed beyond any reasonable doubt that our enhanced AsepticSure™ technology can reliably achieve sterilization standards for virtually any bacterial contaminant found in a hospital setting," stated Dr. Michael Shannon, Medizone's Director of Medical Affairs.
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move.
Sign Up for our Free Stock Newsletter
Medizone International, Inc., is a research and development company engaged in developing its AsepticSure™ technology to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. Mock-up trials are scheduled to begin in January for both public (hospital) and government (bio-terrorism countermeasures) applications.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
